Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2487-2493

  Lambert Niclot, Sidonie ^a   Masquelier, Bernard ^b   Cohen codar, Isabelle ^c   Soulie, Cathia ^a   Delaugerre, Constance ^d   Morand Joubert, Laurence ^a   Charpentier, Charlotte ^e   Ferre, Virginie ^f   Plantier, Jean Christophe ^g   Montes, Brigitte ^h   Carret, Sophie ^c   Perrot, Valerie ⁱ   Peytavin, Gilles ^j   Costagliola, Dominique ^k   Calvez, Vincent ^a   Marcelin, Anne Geneviève ^a   Delamare, C ^l   De Mandela, I ^l   Descamps, D ^j   Dussaix, E ^m   Dubois, D ^m   Schneider, D ⁿ   Segondy, M ^h   Simon, F ^d   Sire, J M ^d   Depatureau, A ^g   Poggi, C ^o   Signori Schmuck, A ^p   Ruffault, A ^q   Carles, M J ^r   Vabret, A ^s   Izopet, J ^t   Nicot, F ^t   Gaba, S ^u   Bocket, L ^v   Cottalorda, J ^w   Le Guillou Guillemette, H ^x   Si Mohamed, A ^e   more..

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b HÔPITAL PELLEGRIN   (France)

^c Abbott   (France)

^d SAINT LOUIS HOSPITAL   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g HÔPITAL CHARLES NICOLLE   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ Lincoln   (France)

^j BICHAT HOSPITAL   (France)

^k INSERM   (France)

^l Hopital Bel Air CHR Metz   (France)

^m HÔPITAL PAUL BROUSSE   (France)

ⁿ HÔPITAL TENON   (France)

^o Groupe Hospitalier la Seyne sur Mer   (France)

^p HÔPITAL MICHALLON   (France)

^q RENNES UNIVERSITY HOSPITAL   (France)

^r DEPARTMENT OF NEUROLOGY   (France)

^s CAEN UNIVERSITY HOSPITAL   (France)

^t CHU PURPAN   (France)

^u St Jean Hospital   (France)

^v LILLE UNIVERSITY HOSPITAL   (France)

^w CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^x ANGERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

HIV 1; Protease inhibitors; Resistance mutations

Indexed keywords

ATAZANAVIR; DARUNAVIR; FOSAMPRENAVIR; LOPINAVIR PLUS RITONAVIR;

ADULT; ANTIRETROVIRAL RESISTANCE; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; FEMALE; FRANCE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL PARAMETERS; OBSERVATIONAL STUDY; RISK ASSESSMENT; TREATMENT FAILURE; VIROLOGICAL FAILURE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, VIRAL; FEMALE; FRANCE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RITONAVIR; TREATMENT FAILURE; VIRAL LOAD;

EID: 84866600988     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks226     Document Type: Article

References (24)

1. Yeni P. Prise en charge médicale des personnes infectées par le VIH. Rapport 2010. http://www.sante-sports.gouv.fr/IMG/pdf/Rapport_2010_sur_la_prise_en_charge_medicale_des_personnes_infectees_par_le_VIH_sous_la_direction_du_Pr-_Patrick_Yeni.pdf (1 December 2010, date last accessed).
2. Carrillo A, Stewart KD, Sham HL et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998; 72: 7532-41.
3. Mo H, Lu L, Dekhtyar T et al. Characterization of resistant HIV variants generated by in vitro passage with lopinavir/ritonavir. Antiviral Res 2003; 59: 173-80.
4. Kempf DJ, King MS, Bernstein B et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004; 189: 51-60.
5. Conradie F, Sanne I, Venter W et al. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS 2004; 18: 1084-5.
6. Friend J, Parkin N, Liegler T. et al. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004; 18: 1965-6.
7. Nijhuis M, Wensing AM, Bierman WF. et al. Failure of treatmentwith first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V. J Infect Dis 2009; 200: 698-709.
8. Delaugerre C, Flandre P, Chaix ML et al. Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009; 53: 2934-9.
9. Hill A, Marcelin AG, Calvez V. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ ritonavir in the TITAN trial. HIV Med 2009; 10: 620-6.
10. Maillard A, Chapplain JM, Tribut O et al. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. J Clin Virol 2007; 38: 131-8.
11. Marcelin AG, Cohen-Codar I, King MS et al. Virological and pharmacological parameters predicting the response to lopinavirritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49: 1720-6.
12. Masquelier B, Breilh D, Neau D et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother 2002; 46: 2926-32.
13. de Mendoza C, Valer L, Bacheler L et al. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS 2006; 20: 1071-4.
14. Mo H, King MS, King K et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J Virol 2005; 79: 3329-38.
15. Descamps D, Delaugerre C, Masquelier B et al. Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol 2006; 78: 153-60.
16. Johnson VA, Brun-Vezinet F, Clotet B et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16: 138-45.
17. Marsh KC, Eiden E, McDonald E. Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997; 704: 307-13.
18. King MS, Rode R, Cohen-Codar I et al. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitorexperienced patients. Antimicrob Agents Chemother 2007; 51: 3067-74.
19. Sham HL, Kempf DJ, Molla A et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42: 3218-24.
20. Molla A, Brun S, Mo H et al. Genotypic and phenotypic analysis of viral isolates from subjects with detectable viral load on therapy with ABT-378/ritonavir. Abstract 39. Antiviral Ther 2000; 5 Suppl 3: S30.
21. Kagan R, Shenderovich M, Ramnarayan K et al. Emergence of a novel lopinavir resistance mutation at codon 47 correlates with ARV utilization. Abstract 49. Antiviral Ther 2003; 8 Suppl 1: S54.
22. Delaugerre C, Mathez D, Peytavin G et al. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients. AIDS 2007; 21: 1210-3.
23. Descamps D, Lambert-Niclot S, Marcelin AG et al. Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients. J Antimicrob Chemother 2009; 63: 585-92.
24. Vora S, Marcelin AG, Gunthard HF et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitorexperienced patients. AIDS 2006; 20: 35-40.